AstraZeneca Pharma India has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for the additional indication of Olaparib film coated tablets of 100mg / 150mg (Lynparza).
Through this approval, Olaparib film coated tablets of 100mg/150mg (Lynparza) in combination with Abiraterone and Prednisone or Prednisolone is indicated for the treatment of adult patients with metastatic castration - resistant prostate cancer.
The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg/150mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |